XML 68 R50.htm IDEA: XBRL DOCUMENT v3.24.4
Issuances of Common Shares and Warrants (Detail Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 02, 2024
Nov. 27, 2024
Nov. 30, 2024
Nov. 30, 2023
Aug. 31, 2024
Agreed to cancelled, Share Purchase warrants     2,977,830    
Description of incentives plan     The Company established an Equity Incentive Plan whereby our Board, pursuant to shareholder approved amendments, may grant up to 1,745,259 stock options to directors, officers, employees, and consultants with such number being increased to up to 10% of the issued share capital at the end of each calendar year, at the discretion of the board, pursuant to an evergreen formula    
Stock based compensation expense     $ 99,415 $ 53,953  
On October 16, 2024 [Member]          
Gross proceeds     5,000,000.0    
Net proceeds     $ 4,500,000    
Agreed to cancelled, Share Purchase warrants     2,917,032    
Description of warrant issuance     We also issued the placement agent warrants to purchase up to 57,190 shares at an exercise price of $3.825 per share    
Issued share purchase warrants     4,551,019    
Purchase common stock shares     4,551,019    
Common stock shares sold     1,633,987    
Purchase price     $ 3.06    
Exercise price     $ 4.75    
On October 2024 [Member]          
Gross proceeds     $ 26,146    
Common stock shares sold     8,402    
Atm share issuance costs     $ 144,812    
Employee Stock [Member]          
Number of shares granted 62,000        
Exercise price $ 3.17        
Granted option vested description options granted vest as follows: 4,000 at grant date, 20,000 on February 28, 2025, and 38,000 over a period of two years        
Weighted Average Remaining Contractual Life 5 years        
Scientific Advisory Board [Member]          
Number of shares granted   20,000      
Exercise price   $ 2.10      
Weighted Average Remaining Contractual Life   5 years      
Stock Options          
Number of shares granted     82,000   696,500
Exercise price     $ 2.91   $ 2.91
Exercise price repriced     $ 3.74    
Non-vested stock options     265,000    
Unrecognized non-cash stock-based compensation expense     $ 627,783    
Weighted Average Remaining Contractual Life     1 year 11 months 19 days